about
Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebratesLigand-regulated binding of FAP68 to the hepatocyte growth factor receptorAgonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagyInterplay between scatter factor receptors and B plexins controls invasive growthPlexin-B3 is a functional receptor for semaphorin 5A.The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis.A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptorAb-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activityAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerGenetic targeting of the kinase activity of the Met receptor in cancer cellsThe MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic targetTankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasivenessHypoxia promotes invasive growth by transcriptional activation of the met protooncogeneFunctional regulation of semaphorin receptors by proprotein convertasesThe endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-MetGab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signalingThe semaphorin 4D receptor controls invasive growth by coupling with MetInvasive growth: a MET-driven genetic programme for cancer and stem cellsInduction of epithelial tubules by growth factor HGF depends on the STAT pathwayThe Met tyrosine kinase receptor in development and cancerTargeting the tumor and its microenvironment by a dual-function decoy Met receptorPlexin A is a neuronal semaphorin receptor that controls axon guidanceUncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle developmentSema4D induces angiogenesis through Met recruitment by Plexin B1Interactions between growth factor receptors and adhesion molecules: breaking the rulesPlexin-B1 plays a redundant role during mouse development and in tumour angiogenesis.Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomasA point mutation in the MET oncogene abrogates metastasis without affecting transformation.HGF: a multifunctional growth factor controlling cell scattering.Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene.Signalling by semaphorin receptors: cell guidance and beyond.Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in miceThe Met oncogene and basal-like breast cancer: another culprit to watch out for?Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibodyReceptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.
P50
Q22010646-8484C1CD-A52B-4DCD-8011-5A06E0652834Q24291722-302E35BC-009F-493A-BD3F-6B89B1633813Q24294894-EB66DD96-F7B2-4C2D-AB4E-1C71B198833DQ24295561-03B679E1-1343-4D2F-8B26-225EB841E1FDQ24297895-21CF255E-A224-473A-8D3F-2E0E40C3519BQ24314397-643EEE56-CFA7-475E-AB96-F71902CA4F64Q24318269-23B5FA49-1428-4413-AF5E-ECB2573ACE90Q24546366-E3E76888-8022-4A27-A080-0CC3537C3785Q24563539-296FFA84-B154-48FA-A7ED-1DD05B75207CQ24675200-E3361FEE-0FEA-4FEA-895B-AE5EEBFDAB0BQ26852906-B2AE588A-4458-432C-93B8-8CA1E5039FFBQ27305064-3FBB7E37-8B78-4D54-8449-9304AB9949BDQ27851787-4D972D97-DFF3-4825-B74C-311694754D8EQ27853380-FB13F3D0-F4CC-4AFE-B929-E0F506F80E68Q28201215-0DB9963F-3732-415A-BCC8-AAC7820B1ABDQ28202069-F4447863-783F-4CF3-BE8E-40CF4C35ED38Q28203827-51C99CB1-5C33-4E9F-8630-7AD2D3153483Q28207199-33D4907B-7195-453C-B9CA-281D61E9008BQ28213808-458EA6DC-5A2F-4151-B9B8-96797F517706Q28219215-67FCAB8C-53A0-4C36-9BAE-AD2605A34E96Q28253680-75C5D18E-2AAB-4E31-AB4D-5217963F4F68Q28259695-DC34C852-2C65-444D-9B0B-A025060647BAQ28263626-38E36FBA-7AA2-4CBB-A7D8-43D09DFAFF69Q28272715-BED7312C-7EED-46EE-A612-5E98BCFC9E8EQ28292881-0077E893-96BE-40AF-BB85-83D19E2AE0E7Q28295203-3824F7FE-669A-4243-8A39-C0124C2DA29CQ28301113-711E85A6-4B11-47FD-A0DB-F9692DA579B9Q28645747-F5C2C4AB-12BE-4E72-BA26-AF3EBFAB1A3EQ33285431-26DC78E9-65E9-4FBF-A29F-90C240C3609EQ33369840-6698427C-3456-4A63-8245-F1336CCA1215Q33563141-E621E607-F26D-41CB-A6E8-4229A1402E7EQ33731936-B46992E7-548A-45E7-B41B-395950EB98EDQ33821093-F70096B5-83C5-4975-B76A-165A5A1E03EBQ33942266-F60AD7F4-5F0E-4C42-90A0-1F2504119BE1Q33992355-40DAE355-3C75-457B-B37A-619D4F93D22DQ33994985-809A7364-EE14-44CF-AB17-85AB87632FA7Q34028716-074CA3E8-A6F8-4BC2-9E2F-61707618F283Q34173500-A3FED8CF-AC76-41B0-A189-C85B82D67280Q34285473-58BDFBA6-4FEE-4334-9D52-D6B3D10088CFQ34314967-42A90DBD-4400-435D-9B8D-7944A8196CDF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Paolo M Comoglio
@nl
Paolo M Comoglio
@sl
Paolo M. Comoglio
@en
Paolo M. Comoglio
@es
type
label
Paolo M Comoglio
@nl
Paolo M Comoglio
@sl
Paolo M. Comoglio
@en
Paolo M. Comoglio
@es
altLabel
Comoglio Paolo M
@en
prefLabel
Paolo M Comoglio
@nl
Paolo M Comoglio
@sl
Paolo M. Comoglio
@en
Paolo M. Comoglio
@es
P214
P106
P1153
7101879270
P21
P214
P31
P396
IT\ICCU\RAVV\081902
P496
0000-0002-7056-5328
P569
1945-01-01T00:00:00Z
P735
P7859
viaf-90298648